Alpelisib Alternatives Compared
| Alpelisib | Verzenio | Ibrance |
|
|---|
| Alpelisib | Verzenio (abemaciclib) | Ibrance (palbociclib) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for PIK3CA-Related Overgrowth Spectrum, Breast Cancer, Breast Cancer - Male. alpelisib may also be used for purposes not listed in this medication guide. |
Prescription only
Verzenio (abemaciclib) is a targeted treatment that helps to reduce the growth and spread of cancer cells in the body. It may be used to treat HR+ HER2-, node-positive, early breast cancer at high... View more |
Prescription only
Ibrance is a CDK4/6 inhibitor that may be used to treat advanced or metastatic hormone-receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer in combination... View more |
Related suggestions Breast Cancer
|
|||||||||||||||
| More about Alpelisib | More about Verzenio (abemaciclib) | More about Ibrance (palbociclib) | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Alpelisib has an average rating of 7.4 out of 10 from a total of 5 ratings on Drugs.com. 80% of reviewers reported a positive effect, while 20% reported a negative effect. |
Verzenio has an average rating of 8.2 out of 10 from a total of 24 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 4% reported a negative effect. |
Ibrance has an average rating of 6.7 out of 10 from a total of 82 ratings on Drugs.com. 62% of reviewers reported a positive effect, while 30% reported a negative effect. |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Side Effects | ||||||||||||||||||
|
See also: alpelisib side effects in more detail. |
See also: Verzenio side effects in more detail. |
See also: Ibrance side effects in more detail. |
||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Verzenio prices |
View all Ibrance prices |
||||||||||||||||
| Dosage Forms Available | ||||||||||||||||||
|
N/A |
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Piqray, Vijoice |
N/A |
N/A |
||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||
|
9 hours |
24.8 hours |
29 hours |
||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 315 drugs are known to interact with alpelisib:
|
A total of 328 drugs are known to interact with Verzenio:
|
A total of 454 drugs are known to interact with Ibrance:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
|
|
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
May 24, 2019 |
September 28, 2017 |
February 03, 2015 |
||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.